AGM
AIM

Alpine Global Management’s AIM ImmunoTech AIM Stock Holding History

Alpine Global Management’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-188
Closed -$38K – 890
2021
Q3 		$38K Buy
+188
New +$38K 0.01% 280

Other funds holding AIM

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alpine Global Management's AIM Position: Q4 2021 in Review

Alpine Global Management sold out of AIM ImmunoTech (AIM) in Q4 2021, closing a stake of 188 shares — an estimated $38K sold.

Alpine Global Management first reported a position in AIM in Q3 2021 and held it in 1 quarter. The position peaked at $38K in Q3 2021. 41 funds tracked by Wall St. Rank hold AIM as of Q4 2021.

  • Alpine Global Management reported no remaining AIM ImmunoTech position as of Q4 2021 after selling out during the quarter.
  • Alpine Global Management sold 188 AIM ImmunoTech shares in Q4 2021, an estimated $38K.
  • Alpine Global Management first reported a position in AIM ImmunoTech in Q3 2021 and held it in 1 quarter.
  • Alpine Global Management's AIM ImmunoTech position peaked at $38K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2021.

Based on Alpine Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.